Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19023183 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL29594923 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL19023208 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL29594633 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL19023080 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL19037346 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL19023239 | 0.83 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL19023240 | 0.83 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3DRD2DRD3 | |
| SCHEMBL4236507 | 0.82 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL19023711 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM2, CHRM5 | SLC6A2 1446/4885SLC6A4 1002/4885SLC6A3 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.